We are currently raising a seed investment round to bring our innovative AVeta device through FDA clearance & conduct US First in Woman clinical trial.
High Potential Market!
The Total Market Potential of Vaginal Atrophy in EU & US is €2.5bn.
Learn More...
If you are an investor and interested in learning more about the AVeta Medical investment opportunity, please complete the form below and you will be contacted by our CEO.
Our Solution
A Revolutionary Device
“With a price point equivalent to vaginal hormone therapy, I see AVeta as disruptive technology”
James A Greenberg
MD, Gynecology
Contact
Send us a Message
Reach us through
Block E, Bioinnovate Building, Floor 2, National University of Ireland, Galway, Ireland.